US Pharma MarketingNew data show VEGF bispecifics could compete with Summit, Akeso drug
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb; and PF Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Much of the attention heading into the annual ASCO meeting next week has focused on Summit Therapeutics and Akeso’s plenary presentation for their bispecific drug ivonescimab.
But two of ivonescimab’s biggest competitors are also releasing ...
Source: Endpoints News